Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
作者信息
Mohan Meera, Becnel Melody Renee, Shah Urvi A, Dong Huaying, Gundarlapalli Sravani, Peterson Timothy, Orozco Jennifer S, Horowitz Sandra, Chhabra Saurabh, Dhakal Binod, Thanendrarajan Sharmilan, Radhakrishnan Sabarinath Venniyil, Al Hadidi Samer, Tan Carlyn, Mailankody Sham, Hultcrantz Malin, Korde Neha, Hassoun Hani, Lesokhin Alexander M, Thomas Sheeba K, Patel Krina K, Manasanch Elisabet E, Weber Donna M, Szabo Aniko, Kaufman Gregory P, Lee Hans C, Zangari Maurizio, van Rhee Frits, Usmani Saad Z, D'Souza Anita, Orlowski Robert Z, Schinke Carolina
机构信息
Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.
The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
出版信息
Am J Hematol. 2022 Jul;97(7):E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2.
Abstract
摘要
相似文献
1
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Am J Hematol. 2022 Jul;97(7):E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2.
2
Daratumumab in multiple myeloma.
Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.
3
Advancement in monoclonal antibody therapy for multiple myeloma.
Lancet Haematol. 2020 May;7(5):e354-e355. doi: 10.1016/S2352-3026(20)30098-3. Epub 2020 Mar 23.
4
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Lancet Haematol. 2020 May;7(5):e381-e394. doi: 10.1016/S2352-3026(19)30249-2. Epub 2020 Mar 11.
5
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
Br J Haematol. 2016 Aug;174(3):473-7. doi: 10.1111/bjh.13776. Epub 2015 Oct 12.
6
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.
7
Isatuximab for the treatment of multiple myeloma.
Drugs Today (Barc). 2021 Nov;57(11):665-675. doi: 10.1358/dot.2021.57.11.3343690.
8
Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.
Eur J Haematol. 2023 Feb;110(2):222-223. doi: 10.1111/ejh.13896. Epub 2022 Nov 20.
9
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420980258. doi: 10.1177/2058738420980258.
10
Targeting NAD Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma.
Trends Cancer. 2020 Jan;6(1):9-12. doi: 10.1016/j.trecan.2019.11.005. Epub 2019 Dec 31.
引用本文的文献
1
CD46-ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts.
Cancers (Basel). 2023 Nov 9;15(22):5335. doi: 10.3390/cancers15225335.
2
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
Blood Adv. 2023 Nov 14;7(21):6430-6440. doi: 10.1182/bloodadvances.2023010162.
3
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma.
Cancers (Basel). 2022 Dec 27;15(1):155. doi: 10.3390/cancers15010155.
本文引用的文献
1
The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma.
Cancers (Basel). 2021 Sep 29;13(19):4909. doi: 10.3390/cancers13194909.
2
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Blood Cancer J. 2021 May 12;11(5):89. doi: 10.1038/s41408-021-00478-4.
3
Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma.
Blood Adv. 2021 Apr 13;5(7):1797-1804. doi: 10.1182/bloodadvances.2020003857.
4
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420980258. doi: 10.1177/2058738420980258.
5
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
6
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15.
7
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Blood. 2019 Jul 11;134(2):123-133. doi: 10.1182/blood-2019-02-895193. Epub 2019 Mar 12.
8
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28.
9
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2.
10
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.
Zotero 插件